<code id='AEDD64E88D'></code><style id='AEDD64E88D'></style>
    • <acronym id='AEDD64E88D'></acronym>
      <center id='AEDD64E88D'><center id='AEDD64E88D'><tfoot id='AEDD64E88D'></tfoot></center><abbr id='AEDD64E88D'><dir id='AEDD64E88D'><tfoot id='AEDD64E88D'></tfoot><noframes id='AEDD64E88D'>

    • <optgroup id='AEDD64E88D'><strike id='AEDD64E88D'><sup id='AEDD64E88D'></sup></strike><code id='AEDD64E88D'></code></optgroup>
        1. <b id='AEDD64E88D'><label id='AEDD64E88D'><select id='AEDD64E88D'><dt id='AEDD64E88D'><span id='AEDD64E88D'></span></dt></select></label></b><u id='AEDD64E88D'></u>
          <i id='AEDD64E88D'><strike id='AEDD64E88D'><tt id='AEDD64E88D'><pre id='AEDD64E88D'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:2
          The cost of healthcare health technology assessment
          APStock

          Physicians are in line to absorb more Medicare cuts next year, while hospital outpatient departments and surgery centers will get billions in new revenue.

          The base figure that determines how much physicians get paid by Medicare will decrease by 3.3% for 2024, the federal government said Thursday.

          advertisement

          The cuts will not be distributed equally among all specialties. Indeed, primary care doctors, endocrinologists, nurse practitioners, and physician assistants would see their Medicare payment rates rise, on average, according to the annual payment rule. Cuts would be steepest for all types of radiologists, including interventionalists and nuclear medicine, as well as vascular surgeons.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news
          Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

          MattRourke/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsle

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Feng Zhang suggests Editas didn’t move quickly enough to find product targets

          ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent